NOSCM-071924 - Dr Edgardo S. Santos with Dr Ahmed Zakari Interview

Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans Summer Cancer Meeting

NOSCM-071924 - Dr E.dgardo S. Santos with Dr Ahmed Zakari Interview

Drs. Santos and Zakari highlighted that tumor-informed ctDNA testing in oligometastatic colorectal cancer can detect minimal residual disease—helping identify patients unlikely to benefit from adjuvant chemotherapy—with repeat assays raising sensitivity to 80–85%. They also noted ASCO’s recent preference for fluorouracil in upper GI adenocarcinomas and underscored ctDNA’s prognostic value in the GALAXY trial.